View Older Stories View More Recent Stories

Sep 30, 2021 07:30AM TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Sep 29, 2021 07:32AM TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in MS at ECTRIMS
Sep 29, 2021 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment a
Sep 23, 2021 08:00AM TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances
Sep 23, 2021 07:30AM TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Sep 20, 2021 07:36AM TG Therapeutics (TGTX) Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia
Sep 20, 2021 07:30AM TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Sep 13, 2021 09:21AM TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Sep 9, 2021 09:00AM TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 30, 2021 07:30AM TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Aug 2, 2021 07:00AM TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
Jul 28, 2021 07:30AM TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update
Jul 9, 2021 07:30AM TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
Jun 29, 2021 07:30AM TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD
Jun 18, 2021 02:00PM TG Therapeutics (TGTX) Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at EAN
Jun 18, 2021 02:00PM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
Jun 18, 2021 07:35AM TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
Jun 11, 2021 07:02AM TG Therapeutics (TGTX) Highlights Data from Phase 1 Study Evaluating TG-1701 as Monotherapy & as Triple Combination w/ Ublituximab & UKONIQ
Jun 11, 2021 07:00AM TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Co
Jun 9, 2021 07:00AM TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
Jun 4, 2021 09:08AM TG Therapeutics (TGTX) Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ
Jun 4, 2021 09:00AM TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annu
May 27, 2021 07:30AM TG Therapeutics to Present at Upcoming Investor Conferences
May 25, 2021 07:03AM TG Therapeutics (TGTX) Announces FDA Acceptance of BLA for Ublituximab in Combination with UKONIQ as Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
May 25, 2021 07:00AM TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and S
May 13, 2021 07:30AM TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 10, 2021 07:00AM TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 6, 2021 07:30AM TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
Apr 26, 2021 07:30AM TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
Apr 26, 2021 07:11AM Samsung Biologics and TG Therapeutics (TGTX) Expand Collaboration for the Large Scale Manufacture of Ublituximab
Apr 26, 2021 07:00AM Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Apr 25, 2021 07:10PM Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
Apr 21, 2021 07:04AM TG Therapeutics (TGTX) Reports Launch of ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ (umbralisib)
Apr 21, 2021 07:00AM TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
Apr 16, 2021 07:32AM TG Therapeutics (TGTX) Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in MS to be Presented at American Academy of Neurology 73rd Annual Meeting
Apr 16, 2021 07:30AM TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
Apr 15, 2021 04:00PM TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Mar 29, 2021 07:44AM TG Therapeutics (TGTX) Completes Rolling Submission of BLA to FDA for Ublituximab in Combination with UKONIQ as Treatment for Patients with Chronic Lymphocytic Leukemia
Mar 29, 2021 07:42AM TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Pati
Mar 9, 2021 07:37AM TG Therapeutics (TGTX) Announces Publication of Results from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with R/R Indolent non-Hodgkin Lymphoma in the Journal of Clinical On
Mar 9, 2021 07:30AM TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journa
Mar 4, 2021 04:30PM TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
Mar 4, 2021 07:30AM TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Mar 2, 2021 07:00AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
Feb 26, 2021 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update
Feb 23, 2021 07:40AM TG Therapeutics (TGTX) Announces Publication of Final Results from Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with R/R High-Risk Chronic Lymphocytic Leukemia in The Lancet
Feb 23, 2021 07:30AM TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia
Feb 5, 2021 01:58PM TG Therapeutics (TGTX) Announces FDA Accelerated Approval of UKONIQ
Feb 5, 2021 01:54PM TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)
Apr 20, 2015 07:40AM Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting
View More Recent Stories View Older Stories